Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Procedural sedation in the emergency department by Italian emergency physicians: results of the SEED SIMEU registry.
Eur J Emerg Med
December 2024
Emergency Department, Azienda Sanitaria Locale Torino 3 (ASL TO3) Ospedale E. Agnelli, Pinerolo.
Background And Importance: Effective and safe procedural sedation is pivotal for the quality of care in the emergency department (ED).
Objectives: The aim of this work is to evaluate the feasibility, effectiveness, and safety procedural sedation performed by emergency physicians in the ED setting in Italy.
Design/setting And Participants/intervention: Following a specific training of the staff and with the adoption of a standardized protocol, a registry of procedural sedations performed on adult patients in 10 Italian EDs was compiled from 2019 to 2022; the following basic data were recorded: demographic and clinical information, procedure's indication, administered drugs, predefined, and actual sedation level.
Tocilizumab and immune signatures for targeted management of cytokine release syndrome in immune checkpoint therapy.
Ann Oncol
December 2024
Centre Hospitalier Universitaire Vaudois (CHUV), University of Lausanne, Department of Medicine, Immunology and Allergy Service, Rue du Bugnon 46, CH-1011 Lausanne, Switzerland. Electronic address:
Article Synopsis
- The study identifies biomarkers that can differentiate between immune-related cytokine release syndrome (irCRS) and sepsis in oncology patients undergoing immune checkpoint inhibitor therapy.
- The analysis revealed that hepatocyte growth factor (HGF) and ferritin are particularly effective in predicting outcomes related to irHLH and Grade 3 irCRS, with a 100% positive and negative predictive value.
- Patients with severe irCRS who did not respond to corticosteroids showed complete resolution after treatment with tocilizumab (TCZ), highlighting the potential for targeted therapies in these cases.
Remission from addiction: erasing the wrong circuits or making new ones?
Nat Rev Neurosci
December 2024
Univ. Bordeaux, CNRS, INCIA, UMR 5287, Bordeaux, France.
Chronic relapse is a hallmark of substance-use disorders (SUDs), but many people with SUDs do recover and eventually enter remission. Many preclinical studies in this field aim to identify interventions that can precipitate recovery by reversing or erasing the neuronal circuit changes caused by chronic drug use. A better understanding of remission from SUDs can also come from preclinical studies that model factors known to influence recovery in humans, such as the negative consequences of drug use and positive environmental influences.
View Article and Find Full Text PDFMicrofluidics in neural extracellular vesicles characterization for early Alzheimer's disease diagnosis.
Mol Cell Neurosci
December 2024
Department of Physiology, Medical College of Wisconsin, Milwaukee, WI 53226, USA. Electronic address:
Article Synopsis
- Dementia encompasses a range of cognitive impairments affecting functions like memory, reasoning, and attention, with Alzheimer's disease being the most prevalent form.
- The current study emphasizes early diagnosis of Alzheimer's through the analysis of neural extracellular vesicles (nEVs), which carry key biomarkers linked to the disease.
- It introduces a microfluidic approach, showcasing how microfluidic devices can efficiently isolate and detect nEVs from minimal samples, enhancing early diagnosis capabilities for Alzheimer's disease.
Hepatoprotective and neuroprotective effects of quinacrine against bile duct ligation-induced hepatic encephalopathy in rats: Role of bone morphogenetic proteins signaling.
Life Sci
December 2024
Department of Pharmacology and Toxicology, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt. Electronic address:
Article Synopsis
- The study evaluated quinacrine, an FDA-approved drug, for its protective effects against hepatic encephalopathy (HE) in a rat model with bile duct ligation (BDL) and focused on the liver-brain communication through BMP2 signaling.
- Results indicated that BDL caused significant liver damage and cognitive deficits in rats, but quinacrine treatment improved liver function and cognitive abilities by restoring crucial signaling pathways.
- The findings suggest that quinacrine may offer potential benefits for treating HE by enhancing liver and brain health, highlighting the role of BMP2 signaling in this process.*
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!